References
1. Gerds AT, Gooley TA, Estey EH, Appelbaum FR, Deeg HJ, Scott BL. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant . Aug 2012;18(8):1211-8. doi:10.1016/j.bbmt.2012.01.009
2. Maher OM, Silva JG, Wu J, et al. Outcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience. Pediatr Transplant . May 2017;21(3)doi:10.1111/petr.12890
3. Locatelli F, Strahm B. How I treat myelodysplastic syndromes of childhood. Blood . Mar 29 2018;131(13):1406-1414. doi:10.1182/blood-2017-09-765214
4. Nakano TA, Lau BW, Dickerson KE, et al. Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium. Pediatr Blood Cancer . Oct 2020;67(10):e28652. doi:10.1002/pbc.28652
5. Strahm B, Nollke P, Zecca M, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia . Mar 2011;25(3):455-62. doi:10.1038/leu.2010.297
6. Kobos R, Steinherz PG, Kernan NA, et al. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia. Biol Blood Marrow Transplant . Mar 2012;18(3):473-80. doi:10.1016/j.bbmt.2011.11.009
7. de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.Cancer . Dec 1 2010;116(23):5420-31. doi:10.1002/cncr.25500
8. Pusic I, Choi J, Fiala MA, et al. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant . Oct 2015;21(10):1761-9. doi:10.1016/j.bbmt.2015.05.026
9. Han S, Kim YJ, Lee J, et al. Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome. J Hematol Oncol . Oct 23 2015;8:118. doi:10.1186/s13045-015-0208-3
10. Oran B, de Lima M, Garcia-Manero G, et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv . Nov 10 2020;4(21):5580-5588. doi:10.1182/bloodadvances.2020002544
11. Wei Y, Xiong X, Li X, et al. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome. Cancer Sci . Sep 2021;112(9):3636-3644. doi:10.1111/cas.15048
12. DeFilipp Z, Chen YB. How I treat with maintenance therapy after allogeneic HCT. Blood . Jan 5 2023;141(1):39-48. doi:10.1182/blood.2021012412
13. Gozdzik J, Rewucka K, Krasowska-Kwiecien A, et al. Adoptive therapy with donor lymphocyte infusion after allogenic hematopoietic SCT in pediatric patients. Bone Marrow Transplant . Jan 2015;50(1):51-5. doi:10.1038/bmt.2014.200
14. Schroeder T, Rautenberg C, Kruger W, et al. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol . Feb 2018;97(2):335-342. doi:10.1007/s00277-017-3185-5
15. Huschart E, Miller H, Salzberg D, et al. Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia.Pediatr Hematol Oncol . Mar 2021;38(2):154-160. doi:10.1080/08880018.2020.1829220
16. Duncan CN, Majhail NS, Brazauskas R, et al. Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation . Jan 01 2015;21(1):151-158. doi:10.1016/j.bbmt.2014.10.006
17. Yoshimi A, Mohamed M, Bierings M, et al. Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia. Leukemia . Mar 2007;21(3):556-60. doi:10.1038/sj.leu.2404537
18. Christopeit M, Kuss O, Finke J, et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol . Sep 10 2013;31(26):3259-71. doi:10.1200/JCO.2012.44.7961
19. Orti G, Sanz J, Bermudez A, et al. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.Biology of Blood and Marrow Transplantation . Mar 2016;22(3):584-588. doi:10.1016/j.bbmt.2015.11.012
20. Vrhovac R, Labopin M, Ciceri F, et al. Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes. Apr 08 2019:1-8. doi:10.1038/bmt.2015.221
21. Ruutu T, de Wreede LC, van Biezen A, et al. Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Apr 08 2019:1-9. doi:10.1038/bmt.2015.186
22. Mehta RS, Rezvani K. Can we make a better match or mismatch with KIR genotyping? Hematology Am Soc Hematol Educ Program . Dec 2 2016;2016(1):106-118. doi:10.1182/asheducation-2016.1.106
23. Davies SM, Iannone R, Alonzo TA, et al. A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children’s Oncology Group AAML05P1 Study. Biol Blood Marrow Transplant . Apr 2020;26(4):712-717. doi:10.1016/j.bbmt.2019.12.723
24. Mamcarz E, Madden R, Qudeimat A, et al. Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution. Bone Marrow Transplant . May 2020;55(5):929-938. doi:10.1038/s41409-019-0750-7
25. Debureaux PE, Labopin M, Mamez AC, et al. Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia. Bone Marrow Transplant . Feb 2020;55(2):452-460. doi:10.1038/s41409-019-0690-2
26. Lane AA. Targeting CD123 in AML. Clin Lymphoma Myeloma Leuk . Sep 2020;20 Suppl 1:S67-S68. doi:10.1016/S2152-2650(20)30466-3
27. Garcia JS, Flamand Y, Tomlinson BK, et al. Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings. Blood . 2020;136(Supplement 1):15-17. doi:10.1182/blood-2020-136235
28. Adema V, Kerr CM, Walter W, et al. Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents? Blood . 2019;134(Supplement_1):1270-1270. doi:10.1182/blood-2019-128967
29. Smith AR, Christiansen EC, Wagner JE, et al. Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS. Pediatr Blood Cancer . Apr 2013;60(4):705-10. doi:10.1002/pbc.24390
30. Winters AC, Maloney KW, Treece AL, Gore L, Franklin AK. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.Pediatr Blood Cancer . Oct 2020;67(10):e28398. doi:10.1002/pbc.28398
31. Karol SE, Alexander TB, Budhraja A, et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.Lancet Oncol . Apr 2020;21(4):551-560. doi:10.1016/S1470-2045(20)30060-7
32. Samra B, Konopleva M, Isidori A, Daver N, DiNardo C. Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions. Front Oncol . 2020;10:562558. doi:10.3389/fonc.2020.562558
33. Place AE, Karol, S.E., Forlenza, C.J., Gambart M., Cooper T.M., Fraser C., Cario G., O’Brien M.M., Gerber N.U., Barnette P., Reinhardt D., Ramsingh G., Tong B., Unnebrink K., Vishwamitra D., Dunbar F., Prine B.A., Palenski T.A., Loh M.L. Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy. presented at: ASH ANNUAL MEETING & EXPOSITION; December 7, 2020 2020;
34. Ghoneim HE, Fan Y, Moustaki A, et al. De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell . Jun 29 2017;170(1):142-157 e19. doi:10.1016/j.cell.2017.06.007
35. Gao L, Zhang Y, Wang S, et al. Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial. J Clin Oncol . Dec 20 2020;38(36):4249-4259. doi:10.1200/JCO.19.03277
36. Ma Y, Qu C, Dai H, et al. Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia. Bone Marrow Transplant . Jun 2020;55(6):1206-1208. doi:10.1038/s41409-019-0677-z
37. Xuan L, Liu Q. Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol . Jan 6 2021;14(1):4. doi:10.1186/s13045-020-01017-7
38. Wei Y, Xiong X, Li X, et al. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome. Cancer Sci . Jun 29 2021;doi:10.1111/cas.15048